<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00465283</url>
  </required_header>
  <id_info>
    <org_study_id>Donepezil-180CTIL</org_study_id>
    <nct_id>NCT00465283</nct_id>
  </id_info>
  <brief_title>Donepezil Double Blind Trial for ECT Memory Disfunction</brief_title>
  <official_title>Donepezil Double Blind Trial for ECT Memory Disfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeerYaakov Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeerYaakov Mental Health Center</source>
  <brief_summary>
    <textblock>
      This is a double blind randomized investigation of donepezil for patients suffering from
      schizophrenia, undergoing ECT.

      Patients will be randomized to receive either donezepil or plasebo, in order to gauge whether
      donezepil has a protective effect on memory disfunction, while patients are treated with ECT.
      Several parameters will be invistigated at baseline: general psychopathological measures,
      memory function scales, side effects scales. The same measurements will be taken throughout
      the trial and one month after ending the ECT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Data will be analyzed using SPSS for Windows.</measure>
    <time_frame>after 5 ECT treatments</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Results of the memory and neurocognitive measures will be examined</measure>
    <time_frame>after 8 ECT treatments</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>using repeated MANOVA with before, within and after ECT treatment.</measure>
    <time_frame>1 month after the last ECT treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorder</condition>
  <arm_group>
    <arm_group_label>Donepezil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment</description>
    <arm_group_label>Donepezil</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Donepezil - Memorit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia, Schizoaffective disorder, schizophreniform disorder patients who meet
             criteria for diagnoses by DSM-IV criteria and evaluated by the Structured Clinical
             Interview for DSM-IV (SCID)

        Exclusion Criteria:

          -  History of serious neurological disorders including neurodegenerative deseases, mental
             retardation, substance and/or alcohol dependence.

          -  Pregnant women

          -  Patients who recieved ECT within 6 month

          -  Patients whith contraindication to Donepezil treatment.

          -  Patients with Lithium treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tali Nachshoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beer Yaakov Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tali Nachshoni, MD</last_name>
    <phone>972-8-9258372</phone>
    <email>bynachshoni@beer-ness.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marina Kupchik, MD</last_name>
    <phone>972-89258382</phone>
    <email>kupchik@beer-ness.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beer Yaakov MHC</name>
      <address>
        <city>Beer Yaacov</city>
        <zip>70350</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tali Nachshoni, M.D.</last_name>
      <phone>972-8-9258372</phone>
      <email>bynachshoni@beer-ness.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tali Nachshoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2007</study_first_submitted>
  <study_first_submitted_qc>April 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2007</study_first_posted>
  <last_update_submitted>January 26, 2009</last_update_submitted>
  <last_update_submitted_qc>January 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marina Kupchik, MD</name_title>
    <organization>BeerYaakov Mental Health Center</organization>
  </responsible_party>
  <keyword>Donepezil, ECT, Memory Disfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

